CBL-514 Research: What Published Studies Have Investigated

What is CBL-514?

What is CBL-514? It is an investigational injectable drug candidate developed by Caliway Biopharmaceuticals, a company based in New Taipei City, Taiwan. In the published trial reports it is described as a small-molecule injection lipolysis agent that acts by inducing apoptosis in adipocytes. It has no marketing approval from any regulator anywhere.

Two facts should be stated together at the top, because they pull in opposite directions and both are true. CBL-514 has more registered and published randomised clinical trial data than almost anything else on this site — the compound has been through a phase 1, several completed phase 2 studies, and a phase 2b with imaging endpoints, all indexed on ClinicalTrials.gov and reported in peer-reviewed journals. And its chemical structure is not in the public record: a PubChem name search returns no compound identifier, and the papers do not give a formula. A reader can read the trials but cannot look up the molecule.

That combination — well-documented clinical programme, undisclosed structure — is normal for a proprietary compound in mid-stage development. It is also the single most important thing to understand before evaluating any research-grade material sold under this name, and the verification section below returns to it.

Origin and development context

The problem the compound was designed for

Injectable agents for localised fat reduction are an established category with one approved member. As Carrion and colleagues note in their 2025 systematic review (PMID 41296813), deoxycholic acid is the only agent with regulatory approval, and only for submental fat. Deoxycholic acid works by detergent-like cytolysis — it disrupts cell membranes non-selectively, which is why its label is narrow and why the field has looked for alternatives with a different mode of action.

CBL-514 was developed against that backdrop, and the mechanistic claim made for it in the published papers is precisely the contrast: apoptosis rather than lysis. Goodman and colleagues titled their 2022 phase 2a report “Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis”, and Lorenc and colleagues (2026) describe the compound as inducing adipocyte apoptosis with, in their words, no observed necrosis or nerve injury in the prior phase 2 studies. Those are the investigators’ characterisations of their own compound, reported here as such.

Where it sits relative to adipotide

CBL-514 is worth reading alongside adipotide, and the contrast is instructive. Both are injectable agents aimed at adipose tissue by an apoptosis mechanism. Adipotide is a peptidomimetic aimed at the vasculature supplying fat, given systemically, whose programme stopped after a primate study documented renal changes and a four-participant human trial terminated. CBL-514 is a small molecule injected locally into the subcutaneous layer, aimed at adipocytes themselves, with a multi-trial programme still running. Same broad idea, entirely different route, entirely different fate so far.

Reference data

This is the shortest reference table in this library, and the omissions are deliberate. Fields that cannot be sourced are left out rather than guessed.

A compound whose identity cannot be independently looked up is a compound whose identity cannot be independently confirmed. That is a factual statement about the public record, not an allegation about any supplier, and it is the reason this page treats verification differently from every other page here.

Mechanisms researchers have examined

The published mechanism account is short because the programme is clinical rather than mechanistic in emphasis. Each point is what the trial reports state:

• Adipocyte apoptosis rather than cytolysis — this is the stated mode of action across all four published trial reports, and it is the distinction the authors draw against detergent-type agents.
• Local rather than systemic action — the protocols deliver the compound directly into subcutaneous adipose tissue at the treatment site. A separate registered phase 2 study (NCT05234736) evaluated the pharmacokinetic profile in healthy volunteers.
• Absence of necrosis or nerve injury as a reported observation — Lorenc and colleagues (2026) state that no necrosis or nerve injury was observed in the preceding phase 2 studies. This is a reported safety observation from those trials, not a mechanistic proof.
• Lipoma tissue as a second target — the Dercum disease study (Herbst and colleagues, 2026) extends the same mechanism to benign adipose tumours rather than normal subcutaneous fat.

What is absent from the peer-reviewed record is the molecular target. No published paper indexed in PubMed identifies the receptor, enzyme or pathway through which CBL-514 is proposed to trigger apoptosis. “Induces adipocyte apoptosis” describes an outcome in tissue, not a mechanism at the molecular level.

What the published trials reported

All four trial publications below carry Caliway Biopharmaceuticals co-authors, and investigator conflict-of-interest disclosures are stated in the papers. Every result is reported here as the investigators’ finding, attributed to them.

Phase 2a, 2022

Goodman, Ho, Chang, Ling and Sheu (Aesthetic Surgery Journal, 2022, PMID 35709509) reported an open-label, randomly allocated phase 2a study with a six-week treatment period and follow-up at four and eight weeks. Participants received one of three unit doses across up to four treatments, each comprising 60 injections into the abdominal adipose layer, and change was assessed by ultrasound. The authors reported that the two higher unit doses were associated with reductions in abdominal fat volume and thickness relative to baseline, and noted that COVID-19 disruption affected recruitment and follow-up. This was an open-label study without a placebo arm.

Placebo-controlled phase 2, 2025

Gold, Schlessinger, Goodman and colleagues (Aesthetic Surgery Journal, 2025, PMID 40037659) reported a single-blind, randomised, placebo-controlled phase 2 trial in 76 participants randomised 2:1, with up to four treatments at four-week intervals and ultrasound assessment. The primary endpoint was the proportion of participants reaching a defined subcutaneous fat volume reduction threshold versus placebo, and the authors reported that a significantly higher proportion of the treated group met it at both follow-up visits, with none in the placebo group meeting it at the eight-week visit. The most common treatment-emergent adverse events reported were injection-site reactions of mild-to-moderate severity.

Phase 2b with MRI, 2026

Lorenc, Gold, Schlessinger and colleagues (Aesthetic Surgery Journal, 2026, PMID 42159040; registry record NCT05736107) reported a randomised, single-blind, placebo-controlled phase 2b trial in 108 adults randomised 1:1 to up to four treatments or placebo at three-week intervals. The primary efficacy measure was the proportion of participants achieving at least a one-grade improvement on a clinician-reported rating scale at twelve weeks, with patient-reported scale and MRI-assessed volume change as secondary endpoints. The authors reported that the treated group exceeded placebo on both rating scales and on MRI-assessed volume change, and that the compound was well tolerated with mainly mild, transient injection-site reactions. The addition of MRI and of blinded clinician- and patient-reported scales makes this the methodologically strongest published study in the programme.

Dercum disease, 2026

Herbst, Ling, Sheu, Schlessinger and Wu (JAAD International, 2026, PMID 41623934) reported a randomised phase 2a study in Dercum disease lipomas — a rare condition involving painful adipose tumours. This is a different clinical question from cosmetic fat reduction and, unlike the abdominal studies, addresses an area with essentially no approved pharmacological options.

The one independent publication

Carrion and colleagues (Plastic and Reconstructive Surgery, 2025, PMID 41296813), a Stanford-led systematic review of injectable lipolytic agents for non-submental fat reduction, included 25 studies covering 3,178 patients across deoxycholic acid, phosphatidylcholine, CBL-514 and other formulations, with formal bias assessment using ROBINS-I and RoB 2. Their conclusion for the category as a whole is that further clinical trials are needed to standardise protocols and evaluate long-term efficacy. It is the only PubMed-indexed publication discussing CBL-514 without sponsor authorship.

Research models and evidence status

Where the programme actually stands

Fifteen CBL-514 studies appear in the ClinicalTrials.gov registry, all sponsored by Caliway. One is phase 1 (NCT04699669, completed). Most are phase 2, several completed, one active and not recruiting, several not yet recruiting. Two are registered as phase 3 and listed as not yet recruiting (including NCT07526974). No phase 3 study has reported results, because none has started.

The precise reading is therefore: a compound with a substantial and genuinely peer-reviewed phase 2 record, entering phase 3 on paper, with no confirmatory trial completed and no approval anywhere.

Company announcements versus published evidence

This distinction deserves its own paragraph because it is where most online writing about this compound goes wrong. A corporate press release announcing topline or interim results is a statement by a party with a financial interest, not reviewed by independent editors or referees, usually without a protocol, a statistical analysis plan, an adverse-event table or a bias assessment. A peer-reviewed trial publication has all of those. Nothing on this page is sourced from a press release, and where this page says a result was reported, it means a named journal published it.

What is not established

The molecular target and mechanism, which no indexed publication identifies. Long-term durability — the published follow-up windows are weeks, not years. Efficacy or safety confirmed by an independent, non-sponsor-affiliated trial, of which none exists. Any regulatory conclusion, since no regulator has reviewed the compound for approval. And the identity of any research-grade material offered under this name, since there is no public structure to match it against. This page makes no efficacy, therapeutic, cosmetic, body-composition or other use claim of any kind, and material is supplied for laboratory research use only — not for human or veterinary use.

How to verify this compound yourself

Verification of CBL-514 is a genuinely harder problem than for anything else in this library, and honesty requires saying why rather than reciting the standard checklist:

• There is no public reference structure — identity confirmation ultimately means comparing a sample against a known structure or a certified reference standard. For a compound with no published formula and no PubChem entry, that comparison cannot be made from public information. This is the central limitation and no certificate can remove it.
• A purity figure is not an identity — an HPLC chromatogram showing a single sharp peak at 99% establishes that the material is one substance. It does not establish which substance. For compounds whose structure is public, mass spectrometry closes that gap; here it cannot be closed by a reader.
• What a certificate can still show — the analytical method used, the retention time, the observed mass, water content and residual solvents, and lot traceability. Those are real data and worth having; they simply cannot substitute for a structure.
• Small-molecule, not peptide, specifications — sequence confirmation, counter-ion content and endotoxin lines belong to peptide certificates. For a small molecule the relevant lines are identity by spectroscopy, chromatographic purity, water and residual solvents.

See how to read a COA for what each certificate line means, and how to verify peptide purity for the peptide workflow this compound does not follow. The exact batch received can be checked on the self-serve verify tool.

Research-grade sourcing and verification

CBL-514 is not held in stock. It appears on our sourcing catalogue as available to order — our supplier lists it, we have not bought it, and material of this kind typically takes about two to three weeks to reach us. For laboratory research use only, it is supplied with a per-batch Certificate of Analysis reporting purity and the analytical method used, verifiable at the lot level, subject to the identity limitation described above. For the vasculature-targeting peptidomimetic studied against the same tissue by an entirely different route, see adipotide research; for a small molecule studied in adipocyte models through NNMT inhibition, see 5-Amino-1MQ research. This is sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. Goodman GJ, Ho WWS, Chang KJ, Ling YF, Sheu AY. “Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction.” Aesthetic Surgery Journal. 2022;42(11):NP662–NP674. PMID 35709509. pubmed.ncbi.nlm.nih.gov/35709509.
2. Gold M, Schlessinger J, Goodman GJ, Dayan S, DuBois J, Ling YF, Sheu AY, Ho WWS, Chou YC. “Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study.” Aesthetic Surgery Journal. 2025;45(6):611–620. PMID 40037659. pubmed.ncbi.nlm.nih.gov/40037659.
3. Lorenc ZP, Gold M, Schlessinger J, et al. “Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment.” Aesthetic Surgery Journal. 2026, online ahead of print. PMID 42159040. pubmed.ncbi.nlm.nih.gov/42159040.
4. Herbst KL, Ling YF, Sheu AY, Schlessinger DI, Wu SY. “Efficacy and safety of CBL-514 for Dercum disease lipomas: A randomized phase 2a study.” JAAD International. 2026;25:1–4. PMID 41623934. pubmed.ncbi.nlm.nih.gov/41623934.
5. Carrion K, Salingaros S, Bernal C, Barger BT, Lipman KJ, How-Volkman C, Thawanyarat K, Nguyen D. “A Systematic Review of Injectable Lipolytic Agents for Non-Submental Fat Reduction.” Plastic and Reconstructive Surgery. 2025, online ahead of print. PMID 41296813. pubmed.ncbi.nlm.nih.gov/41296813.
6. ClinicalTrials.gov. Phase 2b study of CBL-514 injection for abdominal subcutaneous fat reduction, NCT05736107 (Caliway Biopharmaceuticals; completed). clinicaltrials.gov/study/NCT05736107.
7. ClinicalTrials.gov. Phase 1 study of CBL-514 injection, NCT04699669 (Caliway Biopharmaceuticals; completed). clinicaltrials.gov/study/NCT04699669.
8. ClinicalTrials.gov. Phase 3 study of CBL-514 injection for reducing subcutaneous fat, NCT07526974 (Caliway Biopharmaceuticals; listed as not yet recruiting). clinicaltrials.gov/study/NCT07526974.